Investigation of Efficacy of Secukinumab in Patients With Moderate to Serve Atopic Dermatitis

Summary

The overall aim of this study is to assess the effects of a new treatment called Secukinumab in adults suffering from moderate to severe atopic dermatitis. Furthermore, the study shall support the extension of the approval for Secukinumab from psoriasis to atopic dermatitis. The effectiveness of Secukinumab is determined on the reduction of the eczema score EASI 50 (Eczema Area and Severity Index, a tool to measure the severity of atopic dermatitis) at week 4.

Timeline

Start

2018-09-18

Primary completion

2020-05-04

Completion

2020-05-04

Drugs

Indications